Gemcitabine-cisplatin + PD-(L)1 blockade in biliary cancer
Chemotherapy plus immunotherapy is now the first treatment for advanced bile duct cancer, with a small average gain and a minority of long survivors.
TOPAZ-1 (durvalumab, OS HR 0.76) and KEYNOTE-966 (pembrolizumab, OS HR 0.83) both positive; 2-year survival roughly doubled. No predictive biomarker (PD-L1, TMB, MSI) reliably identifies the long-term survivors.
Pages like this
not linked directly; found by shared links- PersonDo-Youn Oh
Shares TOPAZ-1, Gemcitabine + cisplatin, Biliary tract cancer (cholangiocarcinoma).
- TrialABC-02
Shares Gemcitabine + cisplatin, Biliary tract cancer (cholangiocarcinoma).
- TrialHERIZON-BTC-302
Shares Gemcitabine + cisplatin, Biliary tract cancer (cholangiocarcinoma).
- InstitutionIRCCS Humanitas Research Hospital
Shares Biliary tract cancer (cholangiocarcinoma), Immune checkpoint inhibitors.
- CancerCancer of unknown primary (CUP)
Shares Gemcitabine + cisplatin, Immune checkpoint inhibitors.
- CancerNasopharyngeal carcinoma
Shares Gemcitabine + cisplatin, Immune checkpoint inhibitors.
- ProductDostarlimab
Shares Biliary tract cancer (cholangiocarcinoma), Immune checkpoint inhibitors.
- ProductDurvalumab
Shares TOPAZ-1, Biliary tract cancer (cholangiocarcinoma), Immune checkpoint inhibitors.